Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy

NCT01565096 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus Type II

Interventions

DRUG: Metformin
DRUG: Metformin
DRUG: Vildagliptin
DRUG: Glimepiride

Sponsor

ikfe-CRO GmbH

Collaborators

[object Object]
[object Object]